Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 20, 2019updated 21 Feb 2020 1:07pm

IQVIA forms partnership to advance use of real-world data in trials

IQVIA has collaborated with Friends of Cancer Research to advance the use of real-world evidence (RWE) in clinical trials to better understand treatment outcomes over time.

IQVIA has collaborated with Friends of Cancer Research to advance the use of real-world evidence (RWE) in clinical trials to better understand treatment outcomes over time.

According to IQVIA, the research will ascertain whether clinical benefits observed for treatments in clinical trials match with the benefits of the therapies in real-world settings.

RWE uses dynamic data and other assets like EMR, hospital, pharmacy, and claims sources. The research also uses genomics, mobile health, and patient-reported outcomes.

This project is part of the Friends of Cancer Research initiative that works towards demonstrating the application of RWE in cancer research.

A recent study as part of the project saw six US research centres follow protocol to evaluate real-world endpoints in cancer patients. This included time to next treatment, overall survival, time to treatment discontinuation, progression-free survival and time to progression.

The results were published in the JCO Clinical Cancer Informatics and were titled ‘An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer’.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

IQVIA Real-World Solutions chief scientific officer Nancy Dreyer said: “While randomised clinical trials are the gold standard to evaluate whether a medical treatment can work, they don’t determine if treatment works for diverse patients outside the clinical setting and within real-world situations.

“IQVIA is excited to be part of this initiative. This important study demonstrates the value of real-world evidence to measure and quantify the comparative benefits and risks of various medical products.”

Non-identified patient data from administrative claims and electronic health records were used to evaluate real-world endpoints and the researchers found that the results were consistent with results obtained from randomised clinical trials.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU